Irska - angleščina - HPRA (Health Products Regulatory Authority)

lexon (uk) ltd - lamotrigine - chewable/dispersible tablet - 25 milligram(s) - other antiepileptics; lamotrigine

Irska - angleščina - HPRA (Health Products Regulatory Authority)

pco manufacturing - lamotrigine - chewable/dispersible tablet - 100 milligram(s) - other antiepileptics; lamotrigine

Irska - angleščina - HPRA (Health Products Regulatory Authority)

pco manufacturing ltd. - lamotrigine - chewable/dispersible tablet - 50 milligram(s) - other antiepileptics; lamotrigine

Irska - angleščina - HPRA (Health Products Regulatory Authority)

pco manufacturing ltd. - lamotrigine - chewable/dispersible tablet - 100 milligram(s) - other antiepileptics; lamotrigine

Irska - angleščina - HPRA (Health Products Regulatory Authority)

lexon pharmaceuticals (ireland) limited - lamotrigine - chewable/dispersible tablet - 25 milligram(s) - other antiepileptics; lamotrigine

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - lamotrigine, quantity: 25 mg - tablet, dispersible - excipient ingredients: microcrystalline cellulose; sodium starch glycollate; povidone; silicon dioxide; saccharin sodium; mannitol; magnesium stearate; flavour - lamotrigine is an anti-epileptic drug used for the treatment of partial and generalised seizures in adults and children. there is extensive experience with lamotrigine used initially as add-on therapy. lamotrigine has also been found to be effective as monotherapy following withdrawal of concomitant anti-epileptic drugs. initial monotherapy treatment in newly diagnosed paediatric patients is not recommended (see section 5.1 clinical trials).

Malta - angleščina - Medicines Authority

glaxo smithkline ireland limited 12, riverwalk, citywest business campus, dublin 24, ireland - lamotrigine - chewable/dispersible tablet - lamotrigine 2 mg - antiepileptics

Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - lamotrigine 100mg - chewable/dispersible tablet - 100 mg - active: lamotrigine 100mg excipient: aluminium magnesium silicate blackcurrant flavour 502009 ap0551 calcium carbonate hyprolose magnesium stearate povidone saccharin sodium sodium starch glycolate - epilepsy adults (over 12 years of age) lamictal is indicated as adjunctive therapy in the treatment of epilepsy, for partial seizures and generalised seizures, including tonic-clonic seizures and the seizures associated with lennox-gastaut syndrome. children (2 to 12 years of age) lamictal is indicated as adjunctive therapy in the treatment of epilepsy, for partial seizures and generalised seizures including tonic-clonic seizures and the seizures associated with lennox-gaustaut syndrome.

Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - lamotrigine 200mg;   - chewable/dispersible tablet - 200 mg - active: lamotrigine 200mg   excipient: aluminium magnesium silicate blackcurrant flavour 502009 ap0551 calcium carbonate hyprolose magnesium stearate povidone saccharin sodium sodium starch glycolate - epilepsy adults (over 12 years of age) lamictal is indicated as adjunctive therapy in the treatment of epilepsy, for partial seizures and generalised seizures, including tonic-clonic seizures and the seizures associated with lennox-gastaut syndrome. children (2 to 12 years of age) lamictal is indicated as adjunctive therapy in the treatment of epilepsy, for partial seizures and generalised seizures including tonic-clonic seizures and the seizures associated with lennox-gaustaut syndrome.

Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - lamotrigine 2mg - chewable/dispersible tablet - 2 mg - active: lamotrigine 2mg excipient: aluminium magnesium silicate blackcurrant flavour 502009 ap0551 calcium carbonate hyprolose magnesium stearate povidone saccharin sodium sodium starch glycolate - bipolar disorder (adults 18 years of age and over) lamictal is indicated for the prevention of mood episodes in patients with bipolar disorder, predominantly by preventing depressive episodes.